Member Article

Tissue Regenix partnership advances US commercialisation strategy

York-based Tissue Regenix (‘TRX’), the British regenerative medical device company, has announced that it has signed a processing partnership with Community Tissue Services in the United States.

Community Tissue Services is one of the largest tissue banks in the United States, distributing over 230,000 grafts for transplant annually.

Under the terms of the partnership, Community Tissue Services will use Tissue Regenix’s patented dCELL® technology to produce human biological scaffolds initially for use in acute and chronic wound care but ultimately to expand to cover other areas of clinical need.

Tissue Regenix’s dCELL® dermis works by taking human donor skin and removing the DNA and cells, using the patented dCELL® process to leave a dermis matrix that can be placed over the wound to aid natural healing by attracting the patient’s own cells to the wound area.

Recently completed trials in the UK with NHS Blood and Transplant (‘NHSBT’) have shown that patients who have had tough chronic wounds for four and a half years who were treated with Tissue Regenix dCELL® Dermis have seen an 87% reduction in the size of all wounds, while 60% of patients were completely healed with virtually no recurrences.

In the US, chronic wounds affect 6.5 million patients at a cost of care greater than $25bn. The partnership with Community Tissue Services will allow Tissue Regenix to create dCELL® Dermis products in order to target the existing $1.4bn market for wound healing devices and equipment, which is anticipated to reach $1.5bn by 2016.

Antony Odell, managing director of Tissue Regenix, commented: “Tissue Regenix’s partnership with Community Tissue Services will enable us to bring the benefit of dCELL® technology to address a wide range of patient needs.

“This is an important step in our global commercialisation strategy and is a first step in bringing the benefits of dCELL® Technology to the US.

“We remain on course for a US commercial launch of dCELL® Dermis in the first half of 2014.”

This was posted in Bdaily's Members' News section by Mark Lane .